EXTON, Pa.--(BUSINESS WIRE)--Adolor Corporation (Nasdaq:ADLR) announced today the election of Georges Gemayel, Ph.D. to Adolor’s Board of Directors. Dr. Gemayel serves as Executive Vice President Therapeutics of Genzyme Corporation.
“Georges has a great depth of experience in all aspects of drug development, marketing and operations,” stated David Madden, chairman of the board of Adolor. “His career spans international and domestic operations and development for 20 years and we believe he will be invaluable in the continuing development of Adolor.”
